Dynamics of Parkinson's Disease Multimodal Complex Treatment in Germany from 2010⁻2016: Patient Characteristics, Access to Treatment, and Formation of Regional Centers.
Parkinson disease
inpatient treatment
multimodal complex treatment
multiprofessional therapy
Journal
Cells
ISSN: 2073-4409
Titre abrégé: Cells
Pays: Switzerland
ID NLM: 101600052
Informations de publication
Date de publication:
11 02 2019
11 02 2019
Historique:
received:
27
12
2018
revised:
06
02
2019
accepted:
09
02
2019
entrez:
14
2
2019
pubmed:
14
2
2019
medline:
14
2
2019
Statut:
epublish
Résumé
Parkinson's disease (PD) is currently the world's fastest-growing neurological disorder. It is characterized by motor and non-motor symptoms which progressively lead to significant clinical impairment, causing a high burden of disease. In addition to pharmacological therapies, various non-pharmacological treatment options are available. A well established and frequently used multiprofessional inpatient treatment concept in Germany is "Parkinson's disease multimodal complex treatment" (PD-MCT) which involves physiotherapists, occupational therapists, speech therapists, and other specializations for the optimization of treatment in PD (ICD G20) and other Parkinsonian syndromes (ICD G21 and G23). In this study we analyze the PD-MCT characteristics of 55,141 PD inpatients who have been integrated into this therapy concept in Germany in the years 2010⁻2016. We demonstrate that PD-MCT is increasingly applied over this time period. Predominately, PD patients with advanced disease stage and motor fluctuations in age groups between 45 and 69 years were hospitalized. In terms of gender, more male than female patients were treated. PD-MCT is provided primarily in specialized hospitals with high patient numbers but a minor part of all therapies is performed in a rather large number of hospitals with each one treating only a few patients. Access to PD-MCT differs widely across regions, leading to significant migration of patients from underserved areas to PD-MCT centers ⁻ a development that should be considered when implementing such therapies in other countries. Furthermore, our data imply that despite the overall increase in PD-MCT treatments during the observational period, the restricted treatment accessibility may not adequately satisfy current patient´s need.
Identifiants
pubmed: 30754730
pii: cells8020151
doi: 10.3390/cells8020151
pmc: PMC6406830
pii:
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Déclaration de conflit d'intérêts
The authors declare no conflict of interest.
Références
Nervenarzt. 2019 Feb;90(2):167-174
pubmed: 30083879
J Neural Transm (Vienna). 2017 Jun;124(6):715-720
pubmed: 28247031
Eur Neuropsychopharmacol. 2011 Oct;21(10):718-79
pubmed: 21924589
Lancet Neurol. 2017 Jul;16(7):552-563
pubmed: 28653647
Lancet Neurol. 2017 Nov;16(11):877-897
pubmed: 28931491
Fortschr Neurol Psychiatr. 2017 Jun;85(6):329-335
pubmed: 28645125
J Neurol Neurosurg Psychiatry. 2018 Aug;89(8):828-835
pubmed: 29321141
CNS Drugs. 2004;18(2):105-11
pubmed: 14728057
Arch Neurol. 1995 Oct;52(10):1017-22
pubmed: 7575219
Nat Rev Neurosci. 2017 Jul;18(7):435-450
pubmed: 28592904
Nat Rev Dis Primers. 2017 Mar 23;3:17013
pubmed: 28332488
JAMA Neurol. 2018 Jan 1;75(1):9-10
pubmed: 29131880
Lancet Neurol. 2018 Feb;17(2):153-161
pubmed: 29246470
Front Neurol. 2018 Jun 29;9:500
pubmed: 30008693
J Neural Transm (Vienna). 2017 Aug;124(8):1015-1027
pubmed: 28342083
Eur Neurol. 2017;78(3-4):128-136
pubmed: 28746937